499-04-7 Usage
Description
ARECAIDINE BUT-2-YNYL ESTER TOSYLATE is a metabolite of Arecoline, a cholinergic agonist, and is characterized as a crystalline solid. It is a potent and selective muscarinic acetylcholine receptor (mAChR) M2 activator, which makes it a significant compound in the field of pharmaceuticals and neuroscience.
Uses
Used in Pharmaceutical Industry:
ARECAIDINE BUT-2-YNYL ESTER TOSYLATE is used as a selective mAChR M2 activator for its potential role in the treatment of various conditions related to the cholinergic system. Its activation of the M2 receptor can lead to the modulation of cholinergic signaling, which may have therapeutic applications in conditions such as Alzheimer's disease, where cholinergic dysfunction is a prominent feature.
Used in Neuroscience Research:
As a potent and selective mAChR M2 activator, ARECAIDINE BUT-2-YNYL ESTER TOSYLATE is used in neuroscience research to study the function and role of the M2 receptor in cognitive processes and other neurological functions. ARECAIDINE BUT-2-YNYL ESTER TOSYLATE can help researchers understand the underlying mechanisms of cholinergic signaling and develop targeted therapies for neurological disorders.
Used in Drug Development:
ARECAIDINE BUT-2-YNYL ESTER TOSYLATE is used as a lead compound in the development of new drugs targeting the M2 receptor. Its selective activation of the M2 receptor can be exploited to design drugs with improved efficacy and reduced side effects, making it a valuable tool in the development of novel therapeutics for various conditions.
Biological Activity
Potent muscarinic agonist, 4.6-fold selective for M 2 receptors in the atrium versus those in the ileum.
Safety Profile
Mutation data reported. Whenheated to decomposition it emits toxic fumes of NOx.
Check Digit Verification of cas no
The CAS Registry Mumber 499-04-7 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 4,9 and 9 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 499-04:
(5*4)+(4*9)+(3*9)+(2*0)+(1*4)=87
87 % 10 = 7
So 499-04-7 is a valid CAS Registry Number.
InChI:InChI=1/C7H11NO2/c1-8-4-2-3-6(5-8)7(9)10/h3H,2,4-5H2,1H3,(H,9,10)
499-04-7Relevant articles and documents
Iridium-catalyzed enantioselective hydrogenation of unsaturated heterocyclic acids
Song, Song,Zhu, Shou-Fei,Pu, Liu-Yang,Zhou, Qi-Lin
supporting information, p. 6072 - 6075 (2013/07/05)
Spiral binding: A highly enantioselective hydrogenation of unsaturated heterocyclic acids has been developed by using chiral iridium/spirophosphino oxazoline catalysts (see scheme; BArF-=tetrakis[3,5- bis(trifluoromethyl)phenyl]borate, Boc=tert-butoxycarbonyl). This reaction provided an efficient method for the preparation of optically active heterocyclic acids with excellent enantioselectivities. Copyright
New carbamoylpiperidines as human platelet aggregation inhibitors
Guo, Zhengming,Zheng, Xiaozhang,Thompson, Walter,Dugdale, Marion,Gollamudi, Ram
, p. 1041 - 1058 (2007/10/03)
A series of 3-carbamoylpiperidines (nipecotamides) are designed, synthesized and tested for their inhibitory action against adenosine diphosphate (ADP)-induced aggregation of human platelets. A structure- activity analysis of the bis(nipecotamido)aralkane type showed that a substituent on the piperidine ring should preferably be an amide and that the electronegativity of the carbonyl oxygen and the orientation of the amide group affected activities. Based on the knowledge of factors influencing platelet activation and aggregation, a nitric ester moiety which could release nitric oxide (NO) in situ, is incorporated into the nipecotamide structure. These compounds exhibit increased activity compared to those having no -ONO2 function. They also show stereoselectivity, with the meso isomer being approximately twice as potent as the synthetic diastereomeric mixture. Replacement of the -ONO2 function with hydroxyl, ester or alkyl groups considerably diminishes aggregation-inhibitory potential. Nipecotamides are shown here to inhibit the basal and collagen-induced rise in platelet inositol trisphosphate (IP3) levels, as well as phosphoinositide turnover. A comprehensive mechanism of action is proposed taking earlier results into consideration. (C) 2000 Elsevier Science Ltd.